Anika Therapeutics, Inc. Operating Lease Cost
Anika Therapeutics, Inc. (ANIK) reported Operating Lease Cost of $2.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-03
- Anika Therapeutics, Inc. operating lease, cost for the quarter ending 2020-12-31 was $624.00K, a 20.23% increase year-over-year.
- Anika Therapeutics, Inc. operating lease, cost for the quarter ending 2020-09-30 was $590.00K, a 12.38% increase year-over-year.
- Anika Therapeutics, Inc. operating lease, cost for the quarter ending 2020-06-30 was $595.00K, a 14.20% increase year-over-year.
- Anika Therapeutics, Inc. operating lease, cost for the quarter ending 2020-03-31 was $574.00K, a 9.96% increase year-over-year.
- Anika Therapeutics, Inc. operating lease, cost for fiscal 2025 was $2.91M, a 12.69% decline from fiscal 2024.
- Anika Therapeutics, Inc. operating lease, cost for fiscal 2024 was $3.33M, a 0.39% increase from fiscal 2023.
- Anika Therapeutics, Inc. operating lease, cost for fiscal 2023 was $3.32M, a 16.94% increase from fiscal 2022.
- Anika Therapeutics, Inc. operating lease, cost for fiscal 2022 was $2.84M, a 15.03% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.91M 10-K · filed 2026-03-03 | |||
| 2024-12-31 | $3.33M 10-K · filed 2026-03-03 | |||
| 2023-12-31 | $3.32M 10-K · filed 2026-03-03 | |||
| 2022-12-31 | $2.84M 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $2.47M 10-K · filed 2024-03-15 | |||
| 2020-12-31 | $624.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.21M derived: sum of 2 quarters · filed 2023-03-16 | $1.81M derived: sum of 3 quarters · filed 2023-03-16 | $2.38M 10-K · filed 2023-03-16 |
| 2020-09-30 | $590.00K 10-Q · filed 2020-11-05 | $1.19M derived: sum of 2 quarters · filed 2020-11-05 | $1.76M 10-Q · filed 2020-11-05 | $2.28M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $595.00K 10-Q · filed 2020-08-07 | $1.17M 10-Q · filed 2020-08-07 | $1.69M derived: sum of 3 quarters · filed 2022-03-11 | $2.21M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $574.00K 10-Q · filed 2020-05-22 | $1.09M derived: sum of 2 quarters · filed 2022-03-11 | $1.62M derived: sum of 3 quarters · filed 2022-03-11 | $2.14M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $519.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $1.04M derived: sum of 2 quarters · filed 2022-03-11 | $1.56M derived: sum of 3 quarters · filed 2022-03-11 | $2.09M 10-K · filed 2022-03-11 |
| 2019-09-30 | $525.00K 10-Q · filed 2020-11-05 | $1.05M derived: sum of 2 quarters · filed 2020-11-05 | $1.57M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $521.00K 10-Q · filed 2020-08-07 | $1.04M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $522.00K 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |